Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Multicentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study)

NCT04447911 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT04447911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04447911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Multicentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study)
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 4
Overall status
Completed
Start date
February 4, 2021
Completion date
September 17, 2026
Enrollment
113 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hyponatremia, kidney failure, liver failure, siadh